How We’re Mobilizing Our Resources to Help Find Solutions for Covid-19
Learn More
Press Release Archive
-
Results from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST JournalResults from Expert Delphi Consensus Survey on Treatment of Pulmonary Arterial Hypertension (PAH) with Oral Prostacyclin Pathway Agents (PPAs) Published in CHEST JournalPanel of 19 Physicians Provided Consensus Opinions on Clinical Scenarios in Which They Considered Adding Oral PPAs in Patients with PAH on ERA + PDE-5 Inhibitor Background Therapy
-
Johnson & Johnson Postpones 2020 Medical Devices Business Review Due to the CoronavirusJohnson & Johnson Postpones 2020 Medical Devices Business Review Due to the Coronavirus
-
Johnson & Johnson to Host Virtual Annual Meeting of ShareholdersJohnson & Johnson to Host Virtual Annual Meeting of Shareholders
-
Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic UseJohnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic UseJohnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020Johnson & Johnson Will Establish New U.S. Vaccine Manufacturing Capabilities and Additional Production Capacity Outside the U.S. to Begin Production at Risk to Help Ensure Global Vaccine Supply
-
Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity RevascularizationLandmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity RevascularizationXARELTO® has the potential to be the first anticoagulant in 20 years[i] to show a benefit in these high-risk patientsTwo major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease
-
Johnson & Johnson Business Continuity Statement (3/27)Johnson & Johnson Business Continuity Statement (3/27)
-
Janssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIVJanssen Announces Health Canada Approval of CABENUVA™, the First Long-Acting Regimen for the Treatment of HIVCABENUVA™ offers adults living with HIV a new once-monthly injectable option for maintaining viral suppression
-
Janssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific SessionJanssen Highlights Continued Commitment to Cardiovascular & Metabolic Healthcare Solutions with Late-Breaking Data at the First Fully Virtual American College of Cardiology Scientific SessionHighlights include four late-breaking XARELTO® (rivaroxaban) abstractsFour INVOKANA® (canagliflozin) abstracts from the pivotal CREDENCE study will also be presented
-
Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
-
Johnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine DevelopmentJohnson & Johnson Announces Collaboration with the Beth Israel Deaconess Medical Center to Accelerate COVID-19 Vaccine DevelopmentResearch well underway as Janssen scientists collaborate with leading virology laboratory led by Dan Barouch, M.D., Ph.D.